Contact your GP or diabetes specialist if you experience: Severe or worsening fatigue that significantly impairs daily functioning or persists despite self-management strategies Signs of dehydration including dark urine, dizziness, rapid heartbeat, or confusion Symptoms suggesting hypoglycaemia (low blood glucose) such as shakiness, sweating, confusion, or palpitations, particularly if you take insulin or sulfonylureas Persistent nausea or vomiting preventing adequate food or fluid intake Unintentional, rapid, or concerning weight loss , or inability to maintain adequate nutrition Symptoms of nutritional deficiency including pale skin, shortness of breath, tingling in hands or feet, or muscle weakness Seek urgent medical attention if you develop: Severe, persistent abdominal pain (with or without vomiting) may indicate pancreatitis Right upper abdominal pain, fever, or yellowing of skin/eyes possible gallbladder problems Severe dehydration or significantly reduced urination risk of kidney problems Signs of allergic reaction such as rash, swelling, or difficulty breathing Your GP may recommend blood tests to assess for anaemia, thyroid function, kidney function, and other causes of fatigue based on your symptoms

Li X, Song Y, Guo T, Xiao G, Li Q
In November 2025, the Trump Administration announced an upcoming demonstration project that will extend coverage for GLP-1s to people living with obesity and related complications starting later in 2026
Most people will not have any severe side effects if they consume 2 grams or less per day
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials, Diabetes and Metabolism Journal (2019) Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity, JAMA (2022) Once-weekly semaglutide in adults with overweight or obesity, The New England Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes, Obesity and Metabolism (2022) Patient assistance program, Novo Nordisk APC: Find a compounder, Alliance for Pharmacy Compounding (2025) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice